Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3851/IMP3362 http://scihub22266oqcxt.onion/10.3851/IMP3362 32496210!ä!32496210 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antivir+Ther 2020 ; 25 (4): 233-239 Nephropedia Template TP {{tp|p=32496210|t=2020. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19 |pdf=|usr=}}{{32496210}} gab.com Text Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19 JO: Antivir Ther http://www.kidney.de/pget.php?&tw=1&pmid=32496210 #FOAvip Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly infectious and difficult to control. A dual-combination of ribavirin and interferon-alpha has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection. Twit Text FOAVip Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19 ????Antivir Ther http://www.kidney.de/pget.php?&tw=1&pmid=32496210 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32496210 #FOAvip English Wikipedia <ref>{{Cite pmid|32496210}}</ref> Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19 #MMPMID32496210 Xie X; Jiang Y; Zeng Y; Liu H Antivir Ther 2020[]; 25 (4): 233-239 PMID32496210show ga Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly infectious and difficult to control. A dual-combination of ribavirin and interferon-alpha has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Adult[MESH] |Antiviral Agents/*administration & dosage[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Indoles/administration & dosage/adverse effects[MESH] |Interferon-alpha/administration & dosage/adverse effects[MESH] |Lopinavir/administration & dosage/adverse effects[MESH] |Male[MESH]Combination antiviral therapy with lopinavir/ritonavir, arbidol and i(epmc).pdf DeepDyve Pubget Overpricing